Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-09-17 21:35:06 ET · period of report 2026-09-15 · accession 0001789617-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-17 21:35 | 2026-09-15+ | TVTX | Heerma Peter | EVP, Chief COMMERCIAL Off | M - OptEx | $15.69 | +258.2K | 125.3K | New | +$4.05M |
| DMT | 2026-09-17 21:35 | 2026-09-15+ | TVTX | Heerma Peter | EVP, Chief COMMERCIAL Off | S - Sale+OE | $63.06 | -283.2K | 117.1K | -71% | -$17.86M |
| DMT | 2026-09-17 21:35 | 2026-09-15+ | TVTX | Heerma Peter | EVP, Chief COMMERCIAL Off | M - OptEx | $0.00 | -258.2K | 44.8K | -85% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 39,283 | $26.88 | 181,349 | D | — | — | (F1) Includes 1,382 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026. |
| 2 | Common | Common Stock | 2026-09-15 | M | A | 1,381 | $22.40 | 182,730 | D | — | — | |
| 3 | Common | Common Stock | 2026-09-15 | M | A | 36,526 | $8.93 | 219,256 | D | — | — | |
| 4 | Common | Common Stock | 2026-09-15 | S | D | 71,938 | $62.05 | 147,318 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F3) The weighted average sale price for the transaction reported was $62.0517, and the range of prices were between $61.43 and $62.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 5 | Common | Common Stock | 2026-09-15 | S | D | 27,421 | $62.59 | 119,897 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F4) The weighted average sale price for the transaction reported was $62.5936, and the range of prices were between $62.43 and $63.27. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 6 | Common | Common Stock | 2026-09-15 | S | D | 1,400 | $63.65 | 118,497 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F5) The weighted average sale price for the transaction reported was $63.6521, and the range of prices were between $63.56 and $63.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 7 | Common | Common Stock | 2026-09-15 | S | D | 1,431 | $65.31 | 117,066 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F6) The weighted average sale price for the transaction reported was $65.3093, and the range of prices were between $65.30 and $65.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 8 | Common | Common Stock | 2026-09-16 | M | A | 100,000 | $11.25 | 217,066 | D | — | — | |
| 9 | Common | Common Stock | 2026-09-16 | M | A | 55,000 | $15.46 | 272,066 | D | — | — | |
| 10 | Common | Common Stock | 2026-09-16 | M | A | 17,717 | $26.88 | 289,783 | D | — | — | |
| 11 | Common | Common Stock | 2026-09-16 | S | D | 93,604 | $63.25 | 196,179 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F7) The weighted average sale price for the transaction reported was $63.2471, and the range of prices were between $62.50 and $63.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 12 | Common | Common Stock | 2026-09-16 | S | D | 79,113 | $63.65 | 117,066 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F8) The weighted average sale price for the transaction reported was $63.6546, and the range of prices were between $63.50 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 13 | Common | Common Stock | 2026-09-17 | M | A | 8,282 | $22.40 | 125,348 | D | — | — | |
| 14 | Common | Common Stock | 2026-09-17 | S | D | 8,282 | $65.07 | 117,066 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F9) The weighted average sale price for the transaction reported was $65.0709, and the range of prices were between $65.00 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 15 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 39,283 | $0.00 | 18,217 | D | $26.88 · — to 2031-01-21 | 39,283 Common Stock | (F10) The stock option is fully vested and exercisable. |
| 16 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 1,381 | $0.00 | 53,119 | D | $22.40 · — to 2033-01-31 | 1,381 Common Stock | (F11) One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. |
| 17 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 36,526 | $0.00 | 28,474 | D | $8.93 · — to 2034-01-31 | 36,526 Common Stock | (F12) One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter. |
| 18 | Derivative | Employee stock option (right to buy) | 2026-09-16 | M | D | 100,000 | $0.00 | 0 | D | $11.25 · — to 2029-10-01 | 100,000 Common Stock | (F10) The stock option is fully vested and exercisable. |
| 19 | Derivative | Employee stock option (right to buy) | 2026-09-16 | M | D | 55,000 | $0.00 | 0 | D | $15.46 · — to 2030-01-31 | 55,000 Common Stock | (F10) The stock option is fully vested and exercisable. |
| 20 | Derivative | Employee stock option (right to buy) | 2026-09-16 | M | D | 17,717 | $0.00 | 500 | D | $26.88 · — to 2031-01-21 | 17,717 Common Stock | (F10) The stock option is fully vested and exercisable. |
| 21 | Derivative | Employee stock option (right to buy) | 2026-09-17 | M | D | 8,282 | $0.00 | 44,837 | D | $22.40 · — to 2033-01-31 | 8,282 Common Stock | (F11) One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2023, and the remaining shares vest in 36 equal monthly installments thereafter. |